Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

TARS

Tarsus Pharmaceuticals Inc

Apr 17 • 04:00PM ET

34.42

Dollar change -0.48
Percentage change -1.38	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT IHE IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.64	Insider Own	22.67%	Shs Outstand	34.21M	Perf Week	-4.07%
Market Cap	1.29B	Forward P/E	-	EPS next Y	-1.76	Insider Trans	-1.29%	Shs Float	29.00M	Perf Month	12.45%
Income	-135.89M	PEG	-	EPS next Q	-1.18	Inst Own	75.19%	Short Float	27.07%	Perf Quarter	46.97%
Sales	17.45M	P/S	73.97	EPS this Y	11.75%	Inst Trans	1.81%	Short Ratio	10.13	Perf Half Y	145.33%
Book/sh	5.76	P/B	5.98	EPS next Y	56.92%	ROA	-55.01%	Short Interest	7.85M	Perf Year	174.04%
Cash/sh	6.07	P/C	5.68	EPS next 5Y	-	ROE	-69.71%	52W Range	11.33 - 40.40	Perf YTD	69.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-132.82%	ROI	-59.52%	52W High	-14.80%	Beta	1.06
Dividend TTM	-	Quick Ratio	6.85	Sales past 5Y	-17.43%	Gross Margin	85.48%	52W Low	203.80%	ATR (14)	1.94
Dividend Ex-Date	-	Current Ratio	6.93	EPS Y/Y TTM	-80.72%	Oper. Margin	-820.53%	RSI (14)	49.53	Volatility	6.62% 5.51%
Employees	244	Debt/Eq	0.16	Sales Y/Y TTM	-32.42%	Profit Margin	-778.89%	Recom	1.33	Target Price	52.33
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	-157.80%	Payout	-	Rel Volume	0.42	Prev Close	34.90
Sales Surprise	138.99%	EPS Surprise	4.53%	Sales Q/Q	30.76%	Earnings	Feb 27 BMO	Avg Volume	774.92K	Price	34.42
SMA20	-1.66%	SMA50	2.75%	SMA200	56.20%	Trades		Volume	325,635	Change	-1.38%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
04:30PM	Loading…
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
05:00PM	Loading…
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire)
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Jan-21-24 07:01AM	11 Stocks That Will Make You Rich in 5-10 Years (Insider Monkey)
Dec-21-23 03:32PM	Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade (Investor's Business Daily)
Dec-11-23 08:00AM	Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites (GlobeNewswire)
Dec-01-23 11:04PM	Insider Sell Alert: Tarsus Pharmaceuticals Inc's Dianne Whitfield Offloads 8,355 Shares (GuruFocus.com)
Nov-12-23 12:15PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire) -5.86%
Nov-01-23 06:35PM	Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (GlobeNewswire)
Sep-06-23 08:00AM	Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-30-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-24-23 09:00AM	Now Available XDEMVY (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-10-23 04:05PM	Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
02:14PM	Loading…
Aug-03-23 02:14PM	This Tarsus Pharmaceuticals Insider Increased Their Holding In The Last Year (Simply Wall St.)
Aug-01-23 10:30PM	Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -16.99%
Jul-31-23 04:29PM	Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire)
Jul-25-23 07:00AM	FDA Approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis (GlobeNewswire) -24.82%
Jul-20-23 02:04PM	Why Shares of Tarsus Pharmaceuticals Are Up Thursday (Motley Fool) +15.56%
Jul-19-23 08:34PM	Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains? (Zacks) +7.83%
10:13AM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Jun-12-23 08:30AM	Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis (GlobeNewswire)
Jun-05-23 08:30AM	Tarsus to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 04:05PM	Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
May-08-23 08:30AM	Tarsus Launches Dont Freak Out. Get Checked Out. Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers (GlobeNewswire)
May-05-23 08:22AM	Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price (Simply Wall St.)
May-03-23 04:30PM	Tarsus to Participate at the Bank of America 2023 Healthcare Conference (GlobeNewswire)
Apr-24-23 08:30AM	Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer (GlobeNewswire)
Apr-18-23 06:04AM	Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks) +5.25%
Apr-06-23 03:52PM	Shareholders in Tarsus Pharmaceuticals (NASDAQ:TARS) are in the red if they invested a year ago (Simply Wall St.)
Mar-17-23 06:28AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Mar-13-23 04:05PM	Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Mar-09-23 10:00AM	Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-02-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 11:44AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insiders placed bullish bets worth US$1.6m in the last 12 months (Simply Wall St.)
Jan-24-23 04:33AM	Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength? (Zacks)
Dec-16-22 07:00AM	Tarsus Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-15-22 12:45PM	Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease (Benzinga)
08:30AM	Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease (GlobeNewswire)
Dec-08-22 06:55AM	Institutional investors own a significant stake of 41% in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (Simply Wall St.)
Nov-11-22 06:03AM	Tarsus Pharmaceuticals Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.76 loss in 3Q 2021) (Simply Wall St.)
Nov-09-22 08:45AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Oct-25-22 08:30AM	Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 09:26AM	Tarsus Pharmaceuticals (NASDAQ:TARS) investors are sitting on a loss of 40% if they invested a year ago (Simply Wall St.)
Oct-11-22 08:30AM	Tarsus Announces Transition Plans for Board of Directors (GlobeNewswire)
Oct-06-22 08:30AM	Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair (GlobeNewswire)
Sep-29-22 08:30AM	Tarsus Launches Look at the Lids Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis (GlobeNewswire)
Sep-27-22 12:00PM	Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings (GlobeNewswire)
Sep-17-22 10:23AM	The Chief Medical Advisor & Director of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), Elizabeth Lin, Just Bought A Few More Shares (Simply Wall St.)
Sep-07-22 07:00AM	Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Aug-11-22 05:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-22 08:30AM	Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease (GlobeNewswire)
Jul-25-22 08:00AM	Certara Appoints Rosemary Crane as New Independent Board Member (GlobeNewswire)
Jun-29-22 06:51AM	Do Insiders Own Lots Of Shares In Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? (Simply Wall St.)
May-27-22 09:00AM	Tarsus to Present at the Jefferies 2022 Healthcare Conference (GlobeNewswire)
May-14-22 08:19AM	Analysts Just Shipped A Captivating Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Estimates (Simply Wall St.)
May-11-22 06:30AM	The Co-Founder & Independent Chairperson of the Board of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), D. Ackermann, Just Bought 8.3% More Shares (Simply Wall St.)
May-10-22 06:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +11.30%
04:05PM	Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
May-09-22 01:49PM	Further weakness as Tarsus Pharmaceuticals (NASDAQ:TARS) drops 39% this week, taking one-year losses to 63% (Simply Wall St.)
May-06-22 09:00AM	Tarsus to Present at Bank of America 2022 Healthcare Conference (GlobeNewswire) -8.05%
May-05-22 08:30AM	Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting (GlobeNewswire) -6.73%
May-03-22 03:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -6.79%
06:58AM	Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
May-02-22 07:01AM	Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire) -23.54%
07:00AM	Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year (GlobeNewswire)
Apr-29-22 09:23PM	Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Apr-26-22 08:30AM	Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting (GlobeNewswire)
Apr-21-22 03:05AM	E3 Metals Initiates Design of Field Pilot (PR Newswire)
Mar-14-22 04:05PM	Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements (GlobeNewswire) -5.90%
Mar-09-22 05:00PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-03-22 09:00AM	Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Feb-02-22 04:30PM	Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03 (GlobeNewswire) -14.15%
07:00AM	Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility (GlobeNewswire)
Jan-04-22 09:00AM	Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors (GlobeNewswire)
Nov-23-21 04:30PM	Tarsus to Participate at Upcoming Virtual Investor Conferences (GlobeNewswire) +7.72%
Nov-10-21 04:30PM	Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021 (GlobeNewswire)
Nov-09-21 04:05PM	Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements (GlobeNewswire)
Nov-05-21 12:04PM	Notable Tarsus Pharmaceuticals Insider Makes $160K Sale (Benzinga)
Nov-04-21 11:28AM	Tarsus Pharmaceuticals Insider Sold $160K In Company Stock (Benzinga)
09:45AM	Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting (GlobeNewswire)
Nov-02-21 05:00PM	Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference (GlobeNewswire) -5.49%

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '24	Sale	30.60	10,415	318,699	26,456	Mar 19 07:05 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '24	Sale	30.60	4,879	149,297	64,767	Mar 19 07:03 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '24	Sale	30.60	4,766	145,840	54,075	Mar 19 07:08 PM
Wahl Bryan	General Counsel	Mar 18 '24	Sale	30.60	4,436	135,742	40,951	Mar 19 07:05 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '24	Sale	30.60	4,314	132,008	34,181	Mar 19 07:04 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 27 '23	Sale	20.22	8,000	161,760	830,106	Dec 29 05:08 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 20 '23	Sale	20.27	40,000	810,623	838,106	Dec 22 05:30 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Dec 20 '23	Sale	20.00	2,252	45,040	2,251	Dec 22 05:32 PM
Goldberg Andrew D.	Director	Dec 15 '23	Buy	18.96	1,000	18,960	3,000	Dec 19 06:30 PM
Wahl Bryan	General Counsel	Nov 30 '23	Sale	16.31	8,356	136,286	31,966	Dec 01 04:55 PM
Whitfield Dianne C.	Chief Human Resources Officer	Nov 30 '23	Sale	16.31	8,355	136,270	26,784	Dec 01 04:58 PM
Whitfield Dianne C.	Chief Human Resources Officer	Nov 29 '23	Option Exercise	0.00	23,920	0	35,139	Dec 01 04:58 PM
Wahl Bryan	General Counsel	Nov 29 '23	Option Exercise	0.00	23,920	0	40,322	Dec 01 04:55 PM
Azamian Bobak R.	President/CEO and Board Chair	Nov 15 '23	Sale	18.37	8,000	146,933	878,106	Nov 17 04:50 PM
Azamian Bobak R.	President/CEO and Board Chair	Oct 18 '23	Sale	13.24	8,000	105,920	886,106	Oct 20 04:41 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Oct 05 '23	Sale	18.00	1,604	28,872	4,503	Oct 06 05:21 PM
Azamian Bobak R.	President/CEO and Board Chair	Sep 20 '23	Sale	17.21	8,000	137,680	894,106	Sep 22 05:30 PM
Azamian Bobak R.	President/CEO and Board Chair	Aug 23 '23	Sale	17.23	8,000	137,840	902,106	Aug 25 05:12 PM
Lin Elizabeth Yeu	Director	Aug 15 '23	Buy	16.80	9,506	159,701	15,866	Aug 17 06:02 PM
Azamian Bobak R.	President/CEO and Board Chair	Jul 19 '23	Sale	20.01	103,900	2,078,984	910,106	Jul 21 05:42 PM
Mottiwala Aziz	Chief Commercial Officer	Jul 19 '23	Sale	20.05	2,400	48,120	45,806	Jul 21 05:46 PM
Azamian Bobak R.	President/CEO and Board Chair	Jul 12 '23	Sale	17.35	9,000	156,150	1,014,006	Jul 14 04:40 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 21 '23	Sale	18.63	8,000	149,040	1,023,006	Jun 23 04:29 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 14 '23	Sale	18.58	9,000	167,220	1,031,006	Jun 16 04:48 PM
Azamian Bobak R.	President/CEO and Board Chair	Jun 08 '23	Sale	20.01	3,100	62,031	1,040,006	Jun 12 05:40 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 08 '23	Sale	20.00	100	2,000	48,086	Jun 12 05:25 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 07 '23	Sale	19.34	2,500	48,350	48,186	Jun 08 07:16 PM
Mottiwala Aziz	Chief Commercial Officer	Jun 06 '23	Sale	18.61	2,143	39,881	50,686	Jun 08 07:16 PM
Azamian Bobak R.	President/CEO and Board Chair	May 17 '23	Sale	15.90	8,000	127,200	1,043,106	May 19 07:08 PM
Azamian Bobak R.	President/CEO and Board Chair	May 10 '23	Sale	16.80	9,000	151,200	1,051,106	May 12 05:08 PM
Azamian Bobak R.	President/CEO and Board Chair	May 01 '23	Sale	15.10	5,841	88,199	1,060,106	May 02 07:06 PM
Azamian Bobak R.	President/CEO and Board Chair	Apr 28 '23	Sale	15.13	4,278	64,726	1,065,947	May 02 07:06 PM
Azamian Bobak R.	President/CEO and Board Chair	Apr 21 '23	Sale	15.03	2,311	34,734	1,070,225	Apr 25 05:22 PM
Greenstein Leonard M.	Chief Financial Officer	Apr 20 '23	Sale	14.02	5,000	70,100	26,785	Apr 21 05:53 PM
Azamian Bobak R.	President/CEO and Board Chair	Apr 19 '23	Sale	13.60	8,000	108,800	1,072,536	Apr 21 05:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TARS

Tarsus Pharmaceuticals Inc

Upgrade your FINVIZ experience